Assessment of pharmacokinetic mycophenolic acid clearance models using Monte Carlo numerical analysis

References

• Abd Rahman, A.N., et al., 2017. Development of improved dosing regimens for mycophenolate mofetil based on population pharmacokinetic analyses in adults with lupus nephritis. European journal of drug metabolism and pharmacokinetics, 42 (6), 993–1004.
   PubMed Web of Science ®Google Scholar
• Atcheson, B.A., et al., 2004. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Therapeutic drug monitoring, 26 (3), 284–286.
   PubMed Web of Science ®Google Scholar
• Catić-Đorđević, A., et al., 2018. Evaluation of gender-based limited sampling methods for tacrolimus exposure after renal transplantation using the Monte Carlo simulation. Pharmazie, 73 (8), 482–485.
   Web of Science ®Google Scholar
• Chen, B., et al., 2019. Population pharmacokinetics and Bayesian estimation of mycophenolic acid exposure in Chinese renal allograft recipients after administration of EC-MPS. Journal of clinical pharmacology, 59 (4), 578–589.
   PubMed Web of Science ®Google Scholar
• Colom, H., et al., 2018. Prediction of free from total mycophenolic acid concentrations in stable renal transplant patients: a population-based approach. Clinical pharmacokinetics, 57 (7), 877–893.
   PubMed Web of Science ®Google Scholar
• Colom, H., et al., 2014. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. Kidney international, 85 (6), 1434–1443.
   PubMed Web of Science ®Google Scholar
• Cremers, S., et al., 2005. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. British journal of clinical pharmacology, 60 (3), 249–256.
   PubMed Web of Science ®Google Scholar
• De Winter, B.C., et al., 2010. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease. Therapeutic drug monitoring, 32 (5), 606–614.
   PubMed Web of Science ®Google Scholar
• De Winter, B.C., et al., 2011. Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. Clinical journal of the American society of nephrology, 6 (3), 656–663.
   PubMed Web of Science ®Google Scholar
• De Winter, B.C., et al., 2012. Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients. Clinical pharmacokinetics, 51 (1), 29–39.
   PubMed Web of Science ®Google Scholar
• De Winter, B.C., et al., 2009. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. Journal of pharmacokinetics and pharmacodynamics, 36 (6), 541–564.
   PubMed Web of Science ®Google Scholar
• Dong, M., et al., 2014. Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. British journal of clinical pharmacology, 78 (5), 1102–1112.
   PubMed Web of Science ®Google Scholar
• Han, N., et al., 2014. Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients. European journal of clinical pharmacology, 70 (10), 1211–1219.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. 2009. KDIGO clinical practice guideline for the care of kidney transplant recipients. American journal of transplantation, 9, S1–S155.
   PubMed Web of Science ®Google Scholar
• Laković, M., et al., 2017. Numerical computation and prediction of electricity consumption in tobacco industry. Facta universitatis, series: mechanical engineering, 15 (3), 457–465.
   Web of Science ®Google Scholar
• Lamba, M., et al., 2010. Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients. Therapeutic drug monitoring, 32 (6), 778–781.
   PubMed Web of Science ®Google Scholar
• Langers, P., et al., 2014. Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation. Therapeutic drug monitoring, 36 (2), 141–147.
   PubMed Web of Science ®Google Scholar
• Le Guellec, C., et al., 2004. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clinical pharmacokinetics, 43 (4), 253–266.
   PubMed Web of Science ®Google Scholar
• Le Meur, Y., et al., 2007. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. American journal of transplantation, 7 (11), 2496–2503.
   PubMed Web of Science ®Google Scholar
• Li, H., et al., 2014. Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil. Biology of blood and marrow transplantation: journal of the American society for blood and marrow transplantation, 20 (8), 1121–1129.
   PubMed Web of Science ®Google Scholar
• Md Dom, Z.I., et al., 2018. Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients. British journal of clinical pharmacology, 84 (10), 2433–2442.
   PubMed Web of Science ®Google Scholar
• Musuamba, F.T., et al., 2012. A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic acid and tacrolimus early after renal transplantation. Journal of clinical pharmacology, 52 (12), 1833–1843.
   PubMed Web of Science ®Google Scholar
• Premaud, A., et al., 2011. Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches. Pharmacological research, 63 (3), 216–224.
   PubMed Web of Science ®Google Scholar
• Rong, Y., et al., 2019a. Population pharmacokinetics of mycophenolic acid co-administered with tacrolimus in corticosteroid-free adult kidney transplant patients. Clinical pharmacokinetics, 58 (11), 1483–1495.
   PubMed Web of Science ®Google Scholar
• Rong, Y., et al., 2019b. Population pharmacokinetic analysis of immediate-release oral tacrolimus co-administered with mycophenolate mofetil in corticosteroid-free adult kidney transplant recipients. European journal of drug metabolism and pharmacokinetics, 44 (3), 409–422.
   PubMed Web of Science ®Google Scholar
• Saint-Marcoux, F., et al., 2011. Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome. Pharmacological research, 63 (5), 423–431.
   PubMed Web of Science ®Google Scholar
• Shaw, L.M., et al., 2000. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. Journal of clinical pharmacology, 40 (6), 624–633.
   PubMed Web of Science ®Google Scholar
• Smits, T.A., et al., 2014. Effects of unbound mycophenolic acid on inosine monophosphate dehydrogenase inhibition in pediatric kidney transplant patients. Therapeutic drug monitoring, 36 (6), 716–723.
   PubMed Web of Science ®Google Scholar
• Spasić, A., et al., 2019. Adverse effects of mycophenolic acid in renal transplant recipients: gender differences. International journal of clinical pharmacy, 41 (3), 776–784.
   PubMed Web of Science ®Google Scholar
• Staatz, C.E., et al., 2005. Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. European journal of clinical pharmacology, 61 (7), 507–516.
   PubMed Web of Science ®Google Scholar
• Staatz, C.E., and Tett, S.E., 2007. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clinical pharmacokinetics, 46 (1), 13–58.
   PubMed Web of Science ®Google Scholar
• Van Hest, R.M., et al., 2007. Time-dependent clearance of mycophenolic acid in renal transplant recipients. British journal of clinical pharmacology, 63 (6), 741–752.
   PubMed Web of Science ®Google Scholar
• Van Hest, R.M., et al., 2005. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clinical pharmacokinetics, 44 (10), 1083–1096.
   PubMed Web of Science ®Google Scholar
• Veličković-Radovanović, R., et al., 2015. Variability of mycophenolic acid elimination in the renal transplant recipients – population pharmacokinetic approach. Renal failure, 37 (4), 652–658.
   PubMed Web of Science ®Google Scholar
• Wang, X.X., et al., 2015. Population pharmacokinetics of mycophenolic acid in lung transplant recipients with and without cystic fibrosis. European journal of clinical pharmacology, 71 (6), 673–679.
   PubMed Web of Science ®Google Scholar
• Wang, X.X., et al., 2017. Population pharmacokinetics of mycophenolic acid and its glucuronide metabolite in lung transplant recipients with and without cystic fibrosis. Xenobiotica , 47 (8), 697–704.
   PubMed Web of Science ®Google Scholar
• Wang, C.X., et al., 2007. Population pharmacokinetics of mycophenolic acid in senile Chinese kidney transplant recipients. Transplantation proceedings, 39 (5), 1392–1395.
   PubMed Web of Science ®Google Scholar
• Woillard, J.B., et al., 2014. Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring. British journal of clinical pharmacology, 78 (4), 867–876.
   PubMed Web of Science ®Google Scholar
• Woillard, J.B., et al., 2018. Pharmacokinetic models to assist the prescriber in choosing the best tacrolimus dose. Pharmacological research, 130, 316–321.
   PubMed Web of Science ®Google Scholar
• Yoshimura, K., et al., 2018. Population pharmacokinetics and pharmacodynamics of mycophenolic acid using the prospective data in patients undergoing hematopoietic stem cell transplantation. Bone marrow transplantation, 53 (1), 44–51.
   PubMed Web of Science ®Google Scholar
• Yu, Z.C., et al., 2017. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients. Acta pharmacologica sinica, 38 (11), 1566–1579.
   PubMed Web of Science ®Google Scholar
• Zeng, L., et al., 2010. Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. British journal of clinical pharmacology, 70 (4), 567–579.
   PubMed Web of Science ®Google Scholar
• Zhou, P.J., et al., 2007. Pharmacokinetics of mycophenolic acid and estimation of exposure using multiple linear regression equations in Chinese renal allograft recipients. Clinical pharmacokinetics, 46 (5), 389–401.
   PubMed Web of Science ®Google Scholar
• Zwart, T.C., et al., 2018. Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device. British journal of clinical pharmacology, 84 (12), 2889–2902.
   PubMed Web of Science ®Google Scholar